| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Obesity | 62 | 2025 | 2248 | 9.190 |
Why?
|
| Weight Loss | 47 | 2024 | 481 | 9.020 |
Why?
|
| Exercise | 53 | 2025 | 816 | 8.000 |
Why?
|
| Bone Density | 47 | 2025 | 319 | 7.380 |
Why?
|
| Caloric Restriction | 32 | 2023 | 83 | 7.140 |
Why?
|
| Life Style | 18 | 2025 | 416 | 4.650 |
Why?
|
| Frail Elderly | 19 | 2022 | 95 | 4.390 |
Why?
|
| Sarcopenia | 13 | 2025 | 41 | 4.280 |
Why?
|
| Exercise Therapy | 17 | 2025 | 154 | 3.900 |
Why?
|
| Hypogonadism | 15 | 2025 | 284 | 3.770 |
Why?
|
| Testosterone | 17 | 2025 | 535 | 3.740 |
Why?
|
| Diet, Reducing | 14 | 2022 | 89 | 3.720 |
Why?
|
| Aging | 25 | 2025 | 1181 | 3.240 |
Why?
|
| Body Composition | 34 | 2024 | 521 | 3.180 |
Why?
|
| Resistance Training | 7 | 2022 | 32 | 2.920 |
Why?
|
| Muscle, Skeletal | 17 | 2025 | 946 | 2.690 |
Why?
|
| Hormone Replacement Therapy | 11 | 2025 | 196 | 2.530 |
Why?
|
| Aged | 100 | 2025 | 19871 | 2.460 |
Why?
|
| Diabetes Mellitus, Type 2 | 15 | 2024 | 1271 | 1.920 |
Why?
|
| Overweight | 7 | 2019 | 364 | 1.840 |
Why?
|
| Oxygen Consumption | 17 | 2021 | 305 | 1.620 |
Why?
|
| Bone and Bones | 9 | 2022 | 267 | 1.560 |
Why?
|
| Bone Remodeling | 10 | 2021 | 54 | 1.520 |
Why?
|
| Dehydroepiandrosterone | 8 | 2018 | 19 | 1.520 |
Why?
|
| Osteoporosis | 9 | 2021 | 117 | 1.510 |
Why?
|
| Body Mass Index | 27 | 2023 | 1565 | 1.480 |
Why?
|
| Incretins | 3 | 2024 | 24 | 1.310 |
Why?
|
| Insulin | 12 | 2017 | 1203 | 1.310 |
Why?
|
| Muscle Strength | 8 | 2020 | 75 | 1.300 |
Why?
|
| Intra-Abdominal Fat | 4 | 2022 | 52 | 1.300 |
Why?
|
| Muscle Proteins | 6 | 2019 | 416 | 1.290 |
Why?
|
| Insulin Resistance | 10 | 2025 | 641 | 1.260 |
Why?
|
| Humans | 153 | 2025 | 125195 | 1.200 |
Why?
|
| Cognition | 6 | 2022 | 728 | 1.180 |
Why?
|
| Quality of Life | 13 | 2025 | 1934 | 1.180 |
Why?
|
| Male | 114 | 2025 | 61526 | 1.170 |
Why?
|
| Fractures, Bone | 4 | 2023 | 188 | 1.120 |
Why?
|
| Diet | 13 | 2021 | 1140 | 0.980 |
Why?
|
| Hip | 5 | 2012 | 16 | 0.980 |
Why?
|
| Combined Modality Therapy | 10 | 2025 | 1242 | 0.970 |
Why?
|
| C-Reactive Protein | 9 | 2023 | 432 | 0.940 |
Why?
|
| Body Weight | 15 | 2017 | 989 | 0.940 |
Why?
|
| Physical Fitness | 5 | 2012 | 90 | 0.940 |
Why?
|
| Frailty | 3 | 2022 | 104 | 0.930 |
Why?
|
| Aged, 80 and over | 25 | 2025 | 6598 | 0.930 |
Why?
|
| Energy Intake | 14 | 2023 | 494 | 0.920 |
Why?
|
| Female | 99 | 2025 | 66807 | 0.850 |
Why?
|
| Blood Glucose | 16 | 2015 | 1131 | 0.840 |
Why?
|
| Healthy Aging | 2 | 2025 | 9 | 0.820 |
Why?
|
| Metabolic Syndrome | 5 | 2021 | 343 | 0.810 |
Why?
|
| Osteocalcin | 6 | 2022 | 42 | 0.790 |
Why?
|
| Physical Endurance | 7 | 2017 | 45 | 0.750 |
Why?
|
| Cellular Senescence | 1 | 2023 | 161 | 0.740 |
Why?
|
| Adiponectin | 4 | 2016 | 114 | 0.730 |
Why?
|
| Estradiol | 6 | 2022 | 532 | 0.710 |
Why?
|
| Leptin | 5 | 2022 | 214 | 0.700 |
Why?
|
| Adiposity | 6 | 2022 | 190 | 0.700 |
Why?
|
| Double-Blind Method | 9 | 2025 | 1637 | 0.680 |
Why?
|
| Glucose Tolerance Test | 12 | 2019 | 208 | 0.680 |
Why?
|
| Absorptiometry, Photon | 13 | 2022 | 178 | 0.670 |
Why?
|
| Behavior Therapy | 2 | 2021 | 256 | 0.670 |
Why?
|
| Transcriptome | 2 | 2025 | 954 | 0.670 |
Why?
|
| Middle Aged | 60 | 2025 | 26928 | 0.670 |
Why?
|
| Sex Hormone-Binding Globulin | 3 | 2017 | 40 | 0.630 |
Why?
|
| Healthy Lifestyle | 1 | 2019 | 31 | 0.610 |
Why?
|
| Adipose Tissue | 8 | 2020 | 465 | 0.610 |
Why?
|
| Osteoporosis, Postmenopausal | 5 | 2007 | 24 | 0.610 |
Why?
|
| Activities of Daily Living | 5 | 2014 | 405 | 0.580 |
Why?
|
| Cardiovascular Diseases | 5 | 2020 | 1970 | 0.570 |
Why?
|
| Lumbar Vertebrae | 4 | 2018 | 112 | 0.570 |
Why?
|
| Adjuvants, Immunologic | 3 | 2006 | 382 | 0.540 |
Why?
|
| Serum Amyloid P-Component | 1 | 2016 | 14 | 0.530 |
Why?
|
| Estrogen Replacement Therapy | 4 | 2003 | 45 | 0.530 |
Why?
|
| Fasting | 2 | 2023 | 294 | 0.530 |
Why?
|
| Insulin-Like Growth Factor I | 8 | 2015 | 341 | 0.510 |
Why?
|
| Vitamin D | 5 | 2022 | 161 | 0.490 |
Why?
|
| Biomarkers | 13 | 2024 | 3091 | 0.480 |
Why?
|
| Energy Metabolism | 8 | 2020 | 766 | 0.450 |
Why?
|
| Vitamin K Deficiency | 1 | 2014 | 3 | 0.440 |
Why?
|
| Vitamin K | 1 | 2014 | 37 | 0.430 |
Why?
|
| Inflammation | 5 | 2023 | 1446 | 0.420 |
Why?
|
| Hormones | 2 | 2011 | 186 | 0.410 |
Why?
|
| Motor Activity | 2 | 2015 | 520 | 0.410 |
Why?
|
| Estrogens, Conjugated (USP) | 2 | 2003 | 14 | 0.400 |
Why?
|
| Precision Medicine | 1 | 2015 | 319 | 0.400 |
Why?
|
| Adult | 36 | 2025 | 29628 | 0.390 |
Why?
|
| Glucose Intolerance | 2 | 2012 | 78 | 0.390 |
Why?
|
| Coronary Disease | 4 | 2020 | 678 | 0.390 |
Why?
|
| Phentermine | 1 | 2011 | 7 | 0.370 |
Why?
|
| Cross-Sectional Studies | 11 | 2023 | 3425 | 0.370 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2012 | 127 | 0.370 |
Why?
|
| Mobility Limitation | 2 | 2025 | 25 | 0.360 |
Why?
|
| Anti-Obesity Agents | 1 | 2011 | 41 | 0.360 |
Why?
|
| Protein Biosynthesis | 2 | 2011 | 663 | 0.350 |
Why?
|
| Longevity | 3 | 2025 | 135 | 0.350 |
Why?
|
| Gastric Inhibitory Polypeptide | 3 | 2016 | 19 | 0.350 |
Why?
|
| Collagen Type I | 7 | 2022 | 112 | 0.350 |
Why?
|
| Fructose | 1 | 2011 | 62 | 0.350 |
Why?
|
| Feeding Behavior | 2 | 2014 | 702 | 0.350 |
Why?
|
| TCF Transcription Factors | 1 | 2009 | 17 | 0.330 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 634 | 0.330 |
Why?
|
| Glucagon-Like Peptide 1 | 2 | 2024 | 69 | 0.330 |
Why?
|
| KATP Channels | 1 | 2009 | 6 | 0.320 |
Why?
|
| Health Promotion | 3 | 2021 | 389 | 0.320 |
Why?
|
| Blood Pressure | 12 | 2019 | 1375 | 0.320 |
Why?
|
| Postmenopause | 3 | 2020 | 126 | 0.320 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 1 | 2009 | 34 | 0.320 |
Why?
|
| Gait | 4 | 2017 | 144 | 0.310 |
Why?
|
| Glucose | 5 | 2022 | 877 | 0.300 |
Why?
|
| Treatment Outcome | 11 | 2025 | 12392 | 0.290 |
Why?
|
| Gene Expression Regulation | 4 | 2020 | 2522 | 0.290 |
Why?
|
| Risk Factors | 15 | 2021 | 10315 | 0.290 |
Why?
|
| C-Peptide | 4 | 2015 | 113 | 0.290 |
Why?
|
| Aromatase | 2 | 2019 | 22 | 0.290 |
Why?
|
| Fatty Liver | 1 | 2009 | 187 | 0.280 |
Why?
|
| Soybean Proteins | 1 | 2007 | 17 | 0.280 |
Why?
|
| Islets of Langerhans | 1 | 2008 | 174 | 0.270 |
Why?
|
| Isoflavones | 1 | 2007 | 45 | 0.270 |
Why?
|
| Missouri | 2 | 2016 | 36 | 0.260 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 3 | 2015 | 32 | 0.260 |
Why?
|
| Abdominal Fat | 3 | 2015 | 19 | 0.260 |
Why?
|
| Medroxyprogesterone Acetate | 2 | 2003 | 16 | 0.260 |
Why?
|
| DNA-Binding Proteins | 2 | 2025 | 2048 | 0.260 |
Why?
|
| Alkaline Phosphatase | 4 | 2010 | 98 | 0.260 |
Why?
|
| Dietary Proteins | 4 | 2019 | 252 | 0.260 |
Why?
|
| Genetic Variation | 2 | 2009 | 1502 | 0.250 |
Why?
|
| Triglycerides | 3 | 2022 | 575 | 0.250 |
Why?
|
| Follow-Up Studies | 5 | 2021 | 5176 | 0.250 |
Why?
|
| Transcription Factors | 3 | 2025 | 2593 | 0.240 |
Why?
|
| Adaptation, Physiological | 6 | 2015 | 271 | 0.240 |
Why?
|
| Diet, Vegetarian | 1 | 2005 | 5 | 0.240 |
Why?
|
| Peptides | 6 | 2017 | 811 | 0.240 |
Why?
|
| Core Binding Factor Alpha 1 Subunit | 1 | 2025 | 9 | 0.240 |
Why?
|
| Interleukin-6 | 4 | 2014 | 420 | 0.230 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2024 | 21 | 0.230 |
Why?
|
| Estrogens | 6 | 2004 | 504 | 0.230 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2022 | 1117 | 0.230 |
Why?
|
| Sex Factors | 5 | 2023 | 1289 | 0.220 |
Why?
|
| Dehydroepiandrosterone Sulfate | 2 | 2020 | 19 | 0.220 |
Why?
|
| Risk | 2 | 2016 | 756 | 0.220 |
Why?
|
| Finite Element Analysis | 1 | 2023 | 28 | 0.220 |
Why?
|
| Wnt Proteins | 1 | 2025 | 194 | 0.220 |
Why?
|
| Hand Strength | 1 | 2023 | 39 | 0.220 |
Why?
|
| Progesterone Congeners | 1 | 2003 | 6 | 0.210 |
Why?
|
| Weight Reduction Programs | 2 | 2021 | 56 | 0.210 |
Why?
|
| Vascular Stiffness | 2 | 2016 | 74 | 0.210 |
Why?
|
| Muscle Weakness | 1 | 2004 | 84 | 0.210 |
Why?
|
| beta Catenin | 1 | 2025 | 204 | 0.210 |
Why?
|
| Biology | 1 | 2023 | 28 | 0.210 |
Why?
|
| Time Factors | 11 | 2019 | 6338 | 0.200 |
Why?
|
| Health Status | 3 | 2017 | 377 | 0.200 |
Why?
|
| Weight Gain | 2 | 2024 | 400 | 0.200 |
Why?
|
| Independent Living | 1 | 2022 | 66 | 0.190 |
Why?
|
| Nutritional Requirements | 2 | 2014 | 181 | 0.190 |
Why?
|
| Proteins | 2 | 2023 | 1036 | 0.190 |
Why?
|
| Adipocytes | 2 | 2020 | 141 | 0.180 |
Why?
|
| Bronchitis, Chronic | 1 | 2021 | 18 | 0.180 |
Why?
|
| Patient Compliance | 4 | 2016 | 473 | 0.180 |
Why?
|
| Hyperglycemia | 1 | 2022 | 225 | 0.170 |
Why?
|
| STAT1 Transcription Factor | 1 | 2020 | 73 | 0.170 |
Why?
|
| Hypoglycemic Agents | 1 | 2024 | 444 | 0.170 |
Why?
|
| Femur Neck | 1 | 2019 | 9 | 0.170 |
Why?
|
| Thigh | 2 | 2013 | 51 | 0.170 |
Why?
|
| Pulmonary Emphysema | 1 | 2021 | 93 | 0.160 |
Why?
|
| Oxidative Stress | 3 | 2023 | 837 | 0.160 |
Why?
|
| Hydrocortisone | 3 | 2016 | 218 | 0.160 |
Why?
|
| Pilot Projects | 3 | 2020 | 1396 | 0.160 |
Why?
|
| Prospective Studies | 8 | 2022 | 6153 | 0.160 |
Why?
|
| Elder Nutritional Physiological Phenomena | 1 | 2019 | 2 | 0.160 |
Why?
|
| Risk Assessment | 4 | 2018 | 3465 | 0.150 |
Why?
|
| Spine | 2 | 2006 | 142 | 0.150 |
Why?
|
| Calcium, Dietary | 1 | 2019 | 37 | 0.150 |
Why?
|
| Exercise Test | 4 | 2017 | 254 | 0.150 |
Why?
|
| Osteoblasts | 2 | 2025 | 149 | 0.150 |
Why?
|
| Cytokines | 2 | 2016 | 1288 | 0.150 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2016 | 3573 | 0.150 |
Why?
|
| United States | 6 | 2021 | 10916 | 0.150 |
Why?
|
| Reference Values | 2 | 2009 | 718 | 0.150 |
Why?
|
| Metabolic Diseases | 1 | 2019 | 130 | 0.140 |
Why?
|
| Comorbidity | 2 | 2018 | 1534 | 0.140 |
Why?
|
| Femur | 3 | 2018 | 67 | 0.140 |
Why?
|
| Insulin-Secreting Cells | 2 | 2009 | 148 | 0.140 |
Why?
|
| Body Fluid Compartments | 1 | 2017 | 19 | 0.140 |
Why?
|
| Physical Conditioning, Human | 1 | 2017 | 4 | 0.140 |
Why?
|
| Postprandial Period | 2 | 2015 | 77 | 0.140 |
Why?
|
| Illinois | 1 | 2016 | 15 | 0.130 |
Why?
|
| Single-Blind Method | 1 | 2017 | 239 | 0.130 |
Why?
|
| Genotype | 4 | 2009 | 2565 | 0.130 |
Why?
|
| Alzheimer Disease | 1 | 2003 | 798 | 0.130 |
Why?
|
| Clinical Trials as Topic | 2 | 2018 | 1099 | 0.130 |
Why?
|
| Menopause | 3 | 2004 | 77 | 0.130 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2016 | 684 | 0.130 |
Why?
|
| Signal Transduction | 4 | 2025 | 4534 | 0.120 |
Why?
|
| Antibodies, Blocking | 1 | 2016 | 61 | 0.120 |
Why?
|
| Diet Therapy | 1 | 2016 | 41 | 0.120 |
Why?
|
| Feasibility Studies | 3 | 2015 | 761 | 0.120 |
Why?
|
| Ventricular Function, Left | 4 | 2007 | 509 | 0.120 |
Why?
|
| Calcitonin | 2 | 1992 | 30 | 0.120 |
Why?
|
| Analysis of Variance | 2 | 2008 | 1020 | 0.120 |
Why?
|
| Time | 2 | 2017 | 92 | 0.120 |
Why?
|
| Muscular Atrophy | 1 | 2016 | 75 | 0.120 |
Why?
|
| Depression | 1 | 2023 | 1237 | 0.120 |
Why?
|
| Exercise Tolerance | 1 | 2015 | 85 | 0.120 |
Why?
|
| Estrogen Receptor alpha | 1 | 2018 | 458 | 0.120 |
Why?
|
| RNA | 2 | 2008 | 570 | 0.120 |
Why?
|
| Walking | 1 | 2017 | 213 | 0.120 |
Why?
|
| Troponin T | 1 | 2016 | 284 | 0.120 |
Why?
|
| Risk Reduction Behavior | 2 | 2013 | 145 | 0.120 |
Why?
|
| Animals | 9 | 2023 | 34234 | 0.110 |
Why?
|
| Endocrine Glands | 1 | 1994 | 10 | 0.110 |
Why?
|
| Nitric Oxide Synthase | 1 | 1995 | 187 | 0.110 |
Why?
|
| Bone Resorption | 3 | 2008 | 42 | 0.110 |
Why?
|
| Calcium | 4 | 2009 | 1102 | 0.110 |
Why?
|
| Collagen | 3 | 2005 | 320 | 0.110 |
Why?
|
| Research Design | 1 | 2018 | 695 | 0.110 |
Why?
|
| Myostatin | 1 | 2013 | 19 | 0.110 |
Why?
|
| Longitudinal Studies | 4 | 2017 | 1324 | 0.110 |
Why?
|
| Asthma | 1 | 2021 | 756 | 0.110 |
Why?
|
| Hip Joint | 1 | 2013 | 37 | 0.110 |
Why?
|
| Receptors, Interleukin-1 | 1 | 1993 | 28 | 0.100 |
Why?
|
| Triiodothyronine | 2 | 2015 | 61 | 0.100 |
Why?
|
| Cognitive Dysfunction | 1 | 2017 | 236 | 0.100 |
Why?
|
| Age Factors | 5 | 2020 | 2823 | 0.100 |
Why?
|
| Leucine | 2 | 2011 | 310 | 0.100 |
Why?
|
| Nutrition Policy | 1 | 2014 | 102 | 0.100 |
Why?
|
| RNA, Messenger | 4 | 2016 | 2820 | 0.100 |
Why?
|
| Calcitriol | 1 | 1993 | 80 | 0.100 |
Why?
|
| Osteosclerosis | 1 | 1992 | 12 | 0.100 |
Why?
|
| Up-Regulation | 2 | 2012 | 867 | 0.100 |
Why?
|
| Interleukin-1 | 1 | 1993 | 142 | 0.100 |
Why?
|
| Substance Abuse, Intravenous | 1 | 1992 | 39 | 0.100 |
Why?
|
| Peptide Fragments | 1 | 2016 | 780 | 0.100 |
Why?
|
| Neurotensin | 1 | 2012 | 4 | 0.100 |
Why?
|
| Acids | 1 | 2012 | 29 | 0.100 |
Why?
|
| Placebos | 2 | 2011 | 241 | 0.100 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 2 | 2009 | 54 | 0.100 |
Why?
|
| Linear Models | 1 | 2014 | 683 | 0.100 |
Why?
|
| Knee Joint | 1 | 2013 | 158 | 0.100 |
Why?
|
| Area Under Curve | 3 | 2008 | 316 | 0.100 |
Why?
|
| Organ Size | 3 | 2012 | 436 | 0.100 |
Why?
|
| Glucagon | 2 | 2012 | 184 | 0.100 |
Why?
|
| Mass Screening | 1 | 2018 | 784 | 0.100 |
Why?
|
| Prevalence | 1 | 2018 | 2458 | 0.090 |
Why?
|
| Residence Characteristics | 1 | 2014 | 278 | 0.090 |
Why?
|
| Surveys and Questionnaires | 3 | 2013 | 3730 | 0.090 |
Why?
|
| Reproducibility of Results | 3 | 2014 | 2893 | 0.090 |
Why?
|
| Tibia | 2 | 2022 | 70 | 0.090 |
Why?
|
| Cholesterol, LDL | 2 | 2019 | 571 | 0.090 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 2 | 2015 | 20 | 0.090 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2013 | 335 | 0.090 |
Why?
|
| Intention to Treat Analysis | 1 | 2011 | 66 | 0.090 |
Why?
|
| Blood Chemical Analysis | 2 | 2011 | 81 | 0.090 |
Why?
|
| Delayed-Action Preparations | 1 | 2011 | 110 | 0.090 |
Why?
|
| Genetic Markers | 1 | 2012 | 603 | 0.090 |
Why?
|
| Drug Combinations | 1 | 2011 | 267 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 824 | 0.080 |
Why?
|
| Dietary Supplements | 1 | 2014 | 472 | 0.080 |
Why?
|
| Vitamin D Deficiency | 1 | 1991 | 73 | 0.080 |
Why?
|
| Regression Analysis | 1 | 2011 | 781 | 0.080 |
Why?
|
| Heart Failure | 3 | 2020 | 2298 | 0.080 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 1 | 2009 | 24 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2016 | 1033 | 0.080 |
Why?
|
| Sulfonylurea Receptors | 1 | 2009 | 13 | 0.080 |
Why?
|
| Receptors, Drug | 1 | 2009 | 38 | 0.080 |
Why?
|
| Glucose Clamp Technique | 1 | 2009 | 76 | 0.080 |
Why?
|
| Models, Biological | 2 | 2011 | 1460 | 0.080 |
Why?
|
| Polymorphism, Genetic | 2 | 2019 | 816 | 0.080 |
Why?
|
| Osteitis | 1 | 2008 | 1 | 0.080 |
Why?
|
| Arthropathy, Neurogenic | 1 | 2008 | 3 | 0.080 |
Why?
|
| Osteolysis | 1 | 2008 | 9 | 0.080 |
Why?
|
| Protein Deficiency | 1 | 2008 | 20 | 0.080 |
Why?
|
| Glucocorticoids | 1 | 1991 | 383 | 0.080 |
Why?
|
| Anaerobic Threshold | 1 | 2008 | 11 | 0.080 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2012 | 553 | 0.080 |
Why?
|
| Intestinal Absorption | 2 | 2008 | 190 | 0.080 |
Why?
|
| Dietary Sucrose | 1 | 2008 | 42 | 0.070 |
Why?
|
| Amino Acids | 2 | 2009 | 668 | 0.070 |
Why?
|
| Sex Characteristics | 4 | 2015 | 313 | 0.070 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2009 | 190 | 0.070 |
Why?
|
| Diabetic Neuropathies | 1 | 2008 | 58 | 0.070 |
Why?
|
| Amino Acid Substitution | 1 | 2009 | 399 | 0.070 |
Why?
|
| Transcription, Genetic | 1 | 2013 | 1699 | 0.070 |
Why?
|
| Parathyroid Hormone | 2 | 2022 | 71 | 0.070 |
Why?
|
| Muscular Diseases | 1 | 2008 | 103 | 0.070 |
Why?
|
| Radioisotopes | 1 | 2007 | 39 | 0.070 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2007 | 79 | 0.070 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2008 | 139 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 1697 | 0.070 |
Why?
|
| Leukocytes | 1 | 2008 | 211 | 0.070 |
Why?
|
| Biopsy | 2 | 2009 | 1238 | 0.070 |
Why?
|
| Prognosis | 3 | 2020 | 4644 | 0.070 |
Why?
|
| Inflammation Mediators | 1 | 2008 | 244 | 0.070 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2008 | 282 | 0.070 |
Why?
|
| Heart Rate | 5 | 2012 | 592 | 0.070 |
Why?
|
| Alcohol Drinking | 1 | 2009 | 346 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2019 | 2637 | 0.060 |
Why?
|
| Arteries | 2 | 2004 | 225 | 0.060 |
Why?
|
| Weight-Bearing | 2 | 2021 | 42 | 0.060 |
Why?
|
| Advisory Committees | 2 | 2018 | 152 | 0.060 |
Why?
|
| Women's Health | 1 | 2007 | 134 | 0.060 |
Why?
|
| Diabetic Foot | 1 | 2008 | 163 | 0.060 |
Why?
|
| New Mexico | 2 | 2017 | 6 | 0.060 |
Why?
|
| Muscle Contraction | 1 | 2006 | 190 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 1290 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 2007 | 278 | 0.060 |
Why?
|
| Endothelium, Vascular | 1 | 2008 | 527 | 0.060 |
Why?
|
| Pregnancy Proteins | 1 | 2005 | 13 | 0.060 |
Why?
|
| Patient Selection | 1 | 2009 | 699 | 0.060 |
Why?
|
| Lipids | 2 | 2015 | 523 | 0.060 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2007 | 584 | 0.060 |
Why?
|
| Waist Circumference | 2 | 2017 | 89 | 0.060 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2004 | 83 | 0.060 |
Why?
|
| Statistics, Nonparametric | 1 | 2005 | 435 | 0.060 |
Why?
|
| Abdomen | 1 | 2004 | 127 | 0.060 |
Why?
|
| Lipid Metabolism | 1 | 2006 | 357 | 0.050 |
Why?
|
| Basal Metabolism | 2 | 2015 | 95 | 0.050 |
Why?
|
| Osteogenesis | 1 | 2025 | 154 | 0.050 |
Why?
|
| Stroke Volume | 2 | 2003 | 490 | 0.050 |
Why?
|
| Smoking | 1 | 2009 | 1051 | 0.050 |
Why?
|
| Rome | 1 | 2023 | 7 | 0.050 |
Why?
|
| Young Adult | 4 | 2019 | 9052 | 0.050 |
Why?
|
| Italy | 1 | 2023 | 100 | 0.050 |
Why?
|
| Postural Balance | 1 | 2004 | 124 | 0.050 |
Why?
|
| DNA | 1 | 2008 | 1608 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2025 | 2107 | 0.050 |
Why?
|
| Demography | 1 | 2003 | 239 | 0.050 |
Why?
|
| Osteoclasts | 1 | 2022 | 55 | 0.050 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2022 | 186 | 0.050 |
Why?
|
| Radiography | 3 | 1992 | 823 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2025 | 547 | 0.050 |
Why?
|
| Consensus | 1 | 2025 | 641 | 0.050 |
Why?
|
| Lung Diseases | 1 | 2025 | 384 | 0.040 |
Why?
|
| Receptors, Interferon | 1 | 2020 | 25 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2021 | 101 | 0.040 |
Why?
|
| Dietary Carbohydrates | 2 | 2014 | 119 | 0.040 |
Why?
|
| Network Meta-Analysis | 1 | 2020 | 27 | 0.040 |
Why?
|
| Leadership | 1 | 2023 | 229 | 0.040 |
Why?
|
| Calorimetry, Indirect | 2 | 2012 | 56 | 0.040 |
Why?
|
| Respiratory Function Tests | 1 | 2021 | 199 | 0.040 |
Why?
|
| Aromatase Inhibitors | 1 | 2020 | 76 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2003 | 1506 | 0.040 |
Why?
|
| Lipoproteins | 1 | 2000 | 180 | 0.040 |
Why?
|
| Psychometrics | 1 | 2003 | 672 | 0.040 |
Why?
|
| Base Sequence | 2 | 1995 | 3103 | 0.040 |
Why?
|
| Musculoskeletal System | 1 | 2019 | 18 | 0.040 |
Why?
|
| Nutrition Surveys | 1 | 2021 | 293 | 0.040 |
Why?
|
| Blood Flow Velocity | 2 | 2012 | 458 | 0.040 |
Why?
|
| Pelvic Bones | 1 | 2018 | 26 | 0.040 |
Why?
|
| Molecular Sequence Data | 2 | 1995 | 3892 | 0.040 |
Why?
|
| RNA Interference | 1 | 2020 | 502 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2020 | 505 | 0.040 |
Why?
|
| Prostate-Specific Antigen | 1 | 2019 | 255 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2020 | 4404 | 0.040 |
Why?
|
| Androgens | 1 | 2020 | 274 | 0.040 |
Why?
|
| Heart | 1 | 2002 | 730 | 0.040 |
Why?
|
| Metabolome | 1 | 2020 | 293 | 0.040 |
Why?
|
| Disease Progression | 1 | 2003 | 2067 | 0.030 |
Why?
|
| Torso | 1 | 2017 | 12 | 0.030 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2017 | 54 | 0.030 |
Why?
|
| Lung | 1 | 2025 | 1496 | 0.030 |
Why?
|
| Apolipoprotein E4 | 1 | 2017 | 45 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2018 | 175 | 0.030 |
Why?
|
| Prostate | 1 | 2019 | 435 | 0.030 |
Why?
|
| Homeostasis | 1 | 2020 | 703 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2016 | 118 | 0.030 |
Why?
|
| Beclin-1 | 1 | 2016 | 26 | 0.030 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2016 | 141 | 0.030 |
Why?
|
| Walk Test | 1 | 2016 | 24 | 0.030 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2016 | 70 | 0.030 |
Why?
|
| Educational Status | 1 | 2017 | 276 | 0.030 |
Why?
|
| Mice | 3 | 2020 | 17632 | 0.030 |
Why?
|
| Diet, Sodium-Restricted | 1 | 1995 | 15 | 0.030 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2016 | 151 | 0.030 |
Why?
|
| Diastole | 2 | 2007 | 176 | 0.030 |
Why?
|
| Hip Fractures | 1 | 2016 | 61 | 0.030 |
Why?
|
| Sodium, Dietary | 1 | 1995 | 36 | 0.030 |
Why?
|
| Body Temperature | 1 | 2015 | 118 | 0.030 |
Why?
|
| Physical Education and Training | 2 | 2005 | 20 | 0.030 |
Why?
|
| Mice, Obese | 1 | 1995 | 71 | 0.030 |
Why?
|
| Heat-Shock Proteins | 1 | 2016 | 195 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2016 | 398 | 0.030 |
Why?
|
| Kidney Glomerulus | 1 | 1995 | 77 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2016 | 294 | 0.030 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2016 | 245 | 0.030 |
Why?
|
| Mastication | 1 | 2014 | 6 | 0.030 |
Why?
|
| Snacks | 1 | 2014 | 19 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2015 | 627 | 0.030 |
Why?
|
| Edible Grain | 1 | 2014 | 45 | 0.030 |
Why?
|
| Thyroid Hormones | 1 | 1994 | 67 | 0.030 |
Why?
|
| Growth Substances | 1 | 1994 | 113 | 0.030 |
Why?
|
| Dietary Fiber | 1 | 2014 | 75 | 0.030 |
Why?
|
| Premenopause | 1 | 1993 | 30 | 0.030 |
Why?
|
| Ascorbic Acid | 1 | 2014 | 78 | 0.030 |
Why?
|
| DNA Primers | 1 | 1995 | 657 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2016 | 377 | 0.030 |
Why?
|
| Mitochondrial Turnover | 1 | 2013 | 3 | 0.030 |
Why?
|
| Quadriceps Muscle | 1 | 2013 | 12 | 0.030 |
Why?
|
| Forkhead Box Protein O3 | 1 | 2013 | 23 | 0.030 |
Why?
|
| 3T3 Cells | 1 | 1993 | 120 | 0.030 |
Why?
|
| Cardiac Output | 2 | 2004 | 171 | 0.030 |
Why?
|
| Hypothalamus | 1 | 1995 | 213 | 0.030 |
Why?
|
| Binding, Competitive | 1 | 1993 | 192 | 0.030 |
Why?
|
| Blotting, Northern | 1 | 1993 | 261 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2013 | 141 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2020 | 3744 | 0.030 |
Why?
|
| Dietary Fats | 1 | 2014 | 294 | 0.020 |
Why?
|
| Osteitis Deformans | 1 | 1992 | 7 | 0.020 |
Why?
|
| Anemia | 1 | 2016 | 339 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 1994 | 320 | 0.020 |
Why?
|
| Lysine | 1 | 1992 | 196 | 0.020 |
Why?
|
| Nutritional Status | 1 | 2014 | 315 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2016 | 511 | 0.020 |
Why?
|
| Antibodies | 1 | 1993 | 374 | 0.020 |
Why?
|
| Hydroxycholecalciferols | 1 | 1991 | 6 | 0.020 |
Why?
|
| Phenotype | 1 | 2021 | 4262 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2013 | 354 | 0.020 |
Why?
|
| Echocardiography | 2 | 2007 | 1056 | 0.020 |
Why?
|
| Hepacivirus | 1 | 1992 | 244 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2014 | 1259 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 1056 | 0.020 |
Why?
|
| Rats | 2 | 2013 | 3727 | 0.020 |
Why?
|
| Keto Acids | 1 | 2009 | 56 | 0.020 |
Why?
|
| Veterans | 1 | 2021 | 1748 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 1992 | 777 | 0.020 |
Why?
|
| Phenylalanine | 1 | 2009 | 128 | 0.020 |
Why?
|
| Pain | 1 | 1992 | 451 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 1993 | 1399 | 0.020 |
Why?
|
| Herpesvirus 4, Human | 1 | 1992 | 676 | 0.020 |
Why?
|
| 5' Untranslated Regions | 1 | 2009 | 58 | 0.020 |
Why?
|
| Blood Proteins | 1 | 2009 | 124 | 0.020 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2016 | 604 | 0.020 |
Why?
|
| Skin Temperature | 1 | 2008 | 17 | 0.020 |
Why?
|
| Thiobarbituric Acid Reactive Substances | 1 | 2008 | 19 | 0.020 |
Why?
|
| Thyroglobulin | 1 | 2008 | 5 | 0.020 |
Why?
|
| Memory | 1 | 2012 | 360 | 0.020 |
Why?
|
| Urine | 1 | 2008 | 90 | 0.020 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2008 | 50 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2009 | 555 | 0.020 |
Why?
|
| Diet Records | 1 | 2008 | 74 | 0.020 |
Why?
|
| Eukaryotic Initiation Factor-4E | 1 | 2008 | 52 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2016 | 1527 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2012 | 919 | 0.020 |
Why?
|
| Hypertension | 1 | 2017 | 1330 | 0.020 |
Why?
|
| Kinetics | 1 | 2009 | 1333 | 0.020 |
Why?
|
| Computers | 1 | 2007 | 68 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2008 | 443 | 0.020 |
Why?
|
| Vasodilation | 1 | 2008 | 192 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2008 | 315 | 0.020 |
Why?
|
| Anthropometry | 1 | 2007 | 197 | 0.020 |
Why?
|
| Isotope Labeling | 1 | 2007 | 105 | 0.020 |
Why?
|
| Echocardiography, Doppler | 1 | 2007 | 171 | 0.020 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2006 | 136 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 1992 | 1153 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2008 | 489 | 0.020 |
Why?
|
| Aerobiosis | 1 | 2005 | 13 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 2004 | 108 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2007 | 471 | 0.010 |
Why?
|
| Lower Extremity | 1 | 2006 | 187 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2004 | 144 | 0.010 |
Why?
|
| Elasticity | 1 | 2004 | 92 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2004 | 258 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2008 | 1631 | 0.010 |
Why?
|
| Rest | 1 | 2003 | 58 | 0.010 |
Why?
|
| Systole | 1 | 2003 | 200 | 0.010 |
Why?
|
| Software | 1 | 2007 | 684 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 2057 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2008 | 3300 | 0.010 |
Why?
|
| Myocardial Contraction | 1 | 2002 | 268 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 2913 | 0.010 |
Why?
|
| Alleles | 1 | 2004 | 1614 | 0.010 |
Why?
|
| Dihydropyridines | 1 | 1995 | 8 | 0.010 |
Why?
|
| Nitrobenzenes | 1 | 1995 | 19 | 0.010 |
Why?
|
| Rats, Inbred SHR | 1 | 1995 | 65 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 1992 | 16353 | 0.010 |
Why?
|
| Angiotensin II | 1 | 1995 | 167 | 0.010 |
Why?
|
| Nephrectomy | 1 | 1995 | 178 | 0.010 |
Why?
|
| Piperazines | 1 | 1995 | 241 | 0.010 |
Why?
|
| Biological Availability | 1 | 1992 | 137 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1992 | 149 | 0.010 |
Why?
|
| Antihypertensive Agents | 1 | 1995 | 414 | 0.010 |
Why?
|